Adhesion receptor antagonists III

ABSTRACT

Novel oxazolidinone derivatives of the formula I ##STR1## in which R 1  is a phenyl radical which is unsubstituted or is monosubstituted by CN, H 2  N--CH 2  --, A 2  N--CH 2  --, H 2  N--C(═NH)--, H 2  N--C(═NH)--NH--, H 2  N--C(═NH)--NH--CH 2  --, HO--NH--C(═NH)-- or HO--NH--C(═NH)--NH--, 
     X is O, S, SO, SO 2 , --NH-- or --NA--, 
     B is ##STR2## or ##STR3## A is alkyl having from 1 to 6 C atoms, 
     R 2  is H, A, Li, Na, K, NH 4  or benzyl, 
     R 3  is H or (CH 2 ) n  --COOR 2 , 
     E is, in each case independently of each other, CH or N, 
     Q is O, S or NH, 
     m is 1, 2 or 3, and 
     n is 0, 1, 2 or 3, 
     and physiologically compatible salts thereof are provided, which inhibit the binding of fibrinogen to the corresponding receptor and can be used for treating thrombosis, stroke, cardiac infarction, inflammations, arteriosclerosis, osteoporosis and also tumors.

SUMMARY OF THE INVENTION

The invention relates to oxazolidinone derivatives of the formula I##STR4## in which R¹ is a phenyl radical which is unsubstituted or ismonosubstituted by CN, H₂ N--CH₂ --, A₂ N--CH₂ --, H₂ N--C(═NH)--, H₂N--C(═NH)--NH--, H₂ N--C(═NH)--NH--CH₂ --, HO--NH--C(═NH)-- orHO--NH--C(═NH)--NH--,

X is O, S, SO, SO₂, --NH-- or--NA--,

B is ##STR5## or ##STR6## A is alkyl having from 1 to 6 C atoms,

R² is H, A, Li, Na, K, NH₄ or benzyl,

R³ is H or (CH₂)_(n) --COOR²,

E is, in each case independently of each other, CH or N,

Q is O, S or NH,

m is 1, 2 or 3, and

n is 0, 1, 2 or 3,

and physiologically compatible salts thereof.

EP-A1-O 381 033 discloses similar compounds.

The object underlying the invention was to provide novel compoundspossessing valuable properties, in particular such compounds as can beused for preparing drugs.

This object was achieved by the invention. It has been found that thecompounds of the formula I, and their solvates and salts, while beingwell tolerated, possess valuable pharmacological properties. Inparticular, they inhibit both the binding of fibrinogen, fibronectin andthe von Willebrand factor to the fibrinogen receptor of the bloodplatelets (glycoprotein lib/Ilia) and the binding of these compounds,and of other adhesive proteins, such as vitronectin, collagen andlaminin, to the corresponding receptors on the surface of various celltypes. The compounds thus exert an influence on cell-cell interactionsand cell-matrix interactions. In particular, they inhibit the formationof blood platelet thrombi and are useful for treating thromboses,stroke, cardiac infarction, inflammations and arteriosclerosis.

The compounds are also suitable as anti-microbial active substanceswhich are able to prevent infections, for example, those initiated bybacteria, fungi or yeasts. The substances can therefore preferably begiven as accompanying anti-microbial active substances, when organismsare subjected to interventions in which exogenous, for example,biomaterials, implants, catheters, or pacemakers, are employed. They actas antiseptics. Anti-microbial activity of the compounds can bedemonstrated by the procedure described by P. Valentin-Weigand et al.,Infection and Immunity, 2851-2855 (1988).

In addition to this, the compounds have an effect on tumor cells bypreventing these cells from metastasizing. They are, therefore, alsouseful as anti-tumor agents.

There is evidence that tumor cells spreading from a solid tumor into thevasculature are carried by microthrombi and thus are protected frombeing detected by cells of the immune system. The second step ofattachment to the vessel wall seems to be facilitated by microthrombi aswell. Since the formation of thrombi is mediated by fibrinogen bindingto the fibrinogen receptor (glycoprotein llb/Illa) on activatedplatelets, fibrinogen-binding inhibitors are expected to be effective asantimetastatics.

Also, since fibrinogen-binding inhibitors are ligands with fibrinogenreceptor on platelets, they can be used as diagnostic tools fordetection and localization of thrombi in the vascular in vivo. Thus, forexample, in accordance with known procedures, the fibrinogen-bindinginhibitors can be labeled with a signal-generating or detectable moietywhereby, once the labeled fibrinogen-binding inhibitor is bound to afibrinogen receptor on platelets, it is possible to detect and locatethrombi.

Fibrinogen-binding inhibitors are also very effective as research toolsfor studying the metabolism of platelets in the different activationstates or intracellular signalling mechanisms of the fibrinogenreceptor. For example, as described above, fibrinogen-binding inhibitorcan be labeled with a signal-generative or detectable moiety. Thefibrinogen-binding inhibitor-signal generating/detectable moietyconjugate can then be employed in vitro as a research tool. By bindingthe conjugate to fibrinogen receptors, it is possible to monitor andstudy the metabolism of platelets, as well as the activation states andsignalling mechanisms of the fibrinogen receptors.

Furthermore, the compounds are suitable for the treatment and theprophylaxis of osteolytic disorders, in particular, osteoporosis, andrestenosis after angioplasty. They can also be used in a supportive rolein wound healing processes and have anti-angiogenetic properties.

The properties of the compounds can be demonstrated using methods whichare described in EP-A 1-0 462 960. The inhibition of the binding offibrinogen to the fibrinogen receptor can be demonstrated by the methodwhich is given in EP-A1-O 381 033. The effect of inhibitingblood-platelet aggregation can be demonstrated in vitro using the methodof Born (Nature, 4832:927-929 (1962)).

The invention furthermore relates to a process for preparing a compoundof the given formula I, as well as its salts, which process ischaracterized in that a compound of the formula II ##STR7## in which R¹has the meaning given in claim 1, and

Z is Cl, Br, I, OH or a reactive esterified OH group, is reacted with acompound of the formula III

in which

B has the above-mentioned meaning, and

Y is OH, SH, NH₂, NAH or a salt-like radical which can be derived fromOH or SH,

or in that a compound of the formula IV

    R.sup.1 --NH--CH.sub.2 --CH(OH)--CH.sub.2 --X--B           IV,

in which

R¹, B and X have the above-mentioned meanings, or one of its reactivederivatives, is reacted with a reactive derivative of carbonic acid, orin that, in order to prepare a guanidino compound of the formula I (R¹=a phenyl radical which is monosubstituted by H₂ N--C(═NH)--NH--), anamino compound corresponding to the formula I, which compound, however,contains an aminophenyl group in place of the radical R¹, is treatedwith an amidinating agent, or in that a compound of the formula I isliberated from one of its functional derivatives by treatment with asolvolyzing or hydrogenolyzing agent, and/or in that, in a compound ofthe formula I, one or both of the radicals R¹ and/or B is/are convertedinto (an) other radical(s) R¹ and/or B, and/or a compound of the formulaI is converted into one of its salts by treatment with an acid or abase.

The compounds of the formula I possess at least one chiral center andcan therefore appear in several enantiomeric forms. All of these forms(for example, D and L forms) and their mixtures (for example, the DLforms) are included in the formula I.

Both hereinbefore and hereinafter, the radicals and/or parameters B, X,R¹ to R³, A, E, Q, Y, Z, m and n have the meanings given in the formulaeI, II or III, unless expressly indicated otherwise.

In the above formulae, the group A has 1-6, preferably 1, 2, 3 or 4, Catoms. Specifically, A, is preferably methyl, ethyl, propyl, isopropyl,butyl, isobutyl, sec-butyl or tert-butyl, and, in addition, pentyl, 1-,2- or 3-methyl-butyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl,hexyl or 1-, 2-, 3- or 4-methylpentyl.

X is preferably O, but also S, NH or NA, for example, N--CH₃, or even SOand SO₂.

R¹ is preferably a phenyl radical which is substituted, as indicatedabove, in the 4-position or else in the 2- or 3-positions; specificpreference is given to 2-, 3- or, in particular, 4-amidinophenyl; 2-, 3-or 4-aminomethylphenyl; 2-, 3- or 4-guanidinomethylphenyl; 2-, 3- or4-cyanophenyl or else 2-, 3- or 4-N-alkylaminomethylphenyl, with, inthese instances, alkyl preferably being methyl or ethyl.

B is preferably monosubstituted or bisubstituted phenyl or pyrrolyl, orelse monosubstituted thienyl, or else pyridinyl, furanyl or pyrimidinylin unsubstituted or substituted form, with the said substituents beingpossible. Specific preference is given to B being 2-, 3- or4-carboxymethyl-, 2-, 3- or 4-methoxycarbonyl-,or-ethoxycarbonyl-phenyl, as well as, preferably,2-carboxymethylthien-4-yl, 2-carboxymethylpyrrol-4-yl,3-carboxymethylpyrrol-4-yl, 2,5-dicarboxymethyl- or2,3-dicarboxymethylpyrrol-4-yl, 2-carboxymethyl-3-carboxy- or2-carboxymethyl-5-carboxypyrrol-4-yl or 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or3,5-dicarboxymethylphenyl, and preferably also the methyl or ethylesters of the aforementioned preferred radicals and also the Li, Na, Kor ammonium salt radicals which can be derived therefrom.

R² is preferably hydrogen, A or Na, while R³ is particularly preferablyH or carboxymethyl. E is preferably CH and Q is preferably S or NH.

The parameters m and n are preferably 1, but also 2 or 3. In addition tothis, the variable n can also be O.

Those compounds of the formula I are preferred in which at least one ofthe given radicals, groups and/or parameters has one of the givenpreferred meanings. Some groups of preferred compounds are those of theformulae Ia to Ij, which conform to the formula I but in which

in Ia, X is 0;

in Ib, X is 0, and

B is 2-, 3- or 4-carboxymethylphenyl;

in Ic, X is 0, and

R¹ is 2-, 3- or 4-amidinophenyl;

in Id, X is NH or NA, and

R¹ is 2-, 3- or 4-amidinophenyl;

in Ie, X is S, and

R¹ is 2-, 3- or 4-amidinophenyl;

in If, X is 0, and

B is 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dicarboxymethylphenyl;

in Ig, X is 0, and

B is 2-carboxymethyl- or 3-carboxymethyl-thien-4-yl or-pyrrol-4-yl;

in Ih, X is 0, and

B is 2,3- or 2,5-dicarboxymethyl- or 2-carboxymethyl-3-carboxy- or2-carboxymethyl- 5-carboxypyrrol-4-yl;

in Ii, X is 0,

B is 2-, 3- or 4-carboxyphenyl, and

R¹ is 2-, 3- or 4-amidinophenyl;

in Ij, X is 0,

B is 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dicarboxymethylphenyl, and

R¹ is 2-, 3- or 4-amidinophenyl.

In addition to this, compounds are preferred which conform perse to theformulae Ia to Ij but in which the carboxyl group of the radical B isreplaced by a methoxycarbonyl or ethoxycarbonyl group.

The compounds of the formula I, and also the starting compounds fortheir preparation, are otherwise prepared by methods, which are knownper se as described in the literature (for example, in the standardworks such as Houben-Weyl, Methoden der organischen Chemie (Methods ofOrganic Chemistry), Georg-Thieme-Verlag, Stuttgart; as well asEP-A1-0381033 which corresponds to U.S. Pat. Nos. 5,084,466 and5,256,812, and EP-A1-0462960which corresponds to U.S. Pat. No.5,053,393), specifically using reaction conditions which are known andare suitable for the reactions mentioned. In addition, alternativemethods which are known per se will be evident to the skilled worker.

If desired, the starting compounds may also be formed in situ, so thatthey are not isolated from the reaction mixture but, instead, furtherreacted immediately to form the compounds of the formula I.

The compounds of the formula I can be obtained by liberating them fromtheir functional derivatives by solvolysis, in particular hydrolysis, orby hydrogenolysis. Those starting compounds are preferred for thesolvolysis or hydrogenolysis which otherwise conform to the formula Ibut which contain corresponding protected amino and/or hydroxyl groupsin place of one or more free amino and/or hydroxyl groups, preferablythose which carry an amino protective group in place of a H atom whichis bonded to an N atom, in particular those which carry an R'--N group,in which R' is an amino protective group, in place of an HN group,and/or those which carry a hydroxyl protective group in place of the Hatom of a hydroxyl group, for example, those which conform to theformula I but which carry a --COOR" group, in which R" is a hydroxylprotective group, in place of a --COOH group.

Several--identical or different--protected amino and/or hydroxyl groupsmay be present in the molecule of the starting compound. If theprotective groups which are present differ from each other, they may, inmany cases, be eliminated selectively.

The expression "amino protective group" is well known and refers togroups which are suitable for protecting (blocking) an amino group fromchemical reactions but which can easily be removed once the desiredchemical reaction has been carried out at another site in the molecule.Especially typical of such groups are unsubstituted or substituted acyl,aryl (e.g., 2,4-dinitrophenyl (DNP)), aralkoxymethyl (e.g.,benzyloxymethyl (BOM)) or aralkyl groups (e.g., benzyl, 4-nitrobenzyl ortriphenylmethyl). Since the amino protective groups are removed afterthe desired reaction (or sequence of reactions), their nature and sizeis otherwise not critical; nevertheless, those having 1-20, inparticular 1-8, C atoms are preferred. In connection with the presentprocess, the expression "acyl group" is to be interpreted in its widestsense. It embraces acyl groups derived from aliphatic, araliphatic,aromatic or heterocyclic carboxylic acids or sulfonic acids, and, inparticular, alkoxycarbonyl, aryloxy-carbonyl and, especially,aralkoxycarbonyl groups. Examples of acyl groups of this kind arealkanoyl, such as acetyl, propionyl or butyryl; aralkanoyl, such asphenylacetyl; aroyl, such as benzoyl or toluoyl; aryloxyalkanoyl, suchas phenoxyacetyl; alkoxycarbonyl, such as methoxycarbonyl,ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, isopropoxycarbonyl,tert-butoxycarbonyl (BOC) or 2-iodoethoxycarbonyl; aralkyloxycarbonyl,such as benzyloxycarbonyl (CBZ), 4-methoxybenzyloxycarbonyl or9-fluorenylmethoxycarbonyl (FMOC). Amino protective groups which arepreferred are BOC, DNP and BOM, and, in addition, CBZ, benzyl andacetyl.

The expression "hydroxyl protective group" is likewise well known andrefers to groups which are suitable for protecting a hydroxyl group fromchemical reactions but which are readily removed once the desiredchemical reaction has been carried out at another site in the molecule.Typical of such groups are the above-mentioned unsubstituted orsubstituted aryl, aralkyl or acyl groups, as are alkyl groups. Thenature and size of the hydroxyl protective groups is not critical sincethey can be removed once again after the desired chemical reaction orsequence of reactions; groups having 1-20, in particular 1-10, C atomsare preferred. Examples of hydroxyl protective groups are, inter alia,tert-butyl, benzyl, p-nitrobenzoyl, p-toluenesulfonyl and acetyl, withbenzyl and acetyl being particularly preferred.

The functional derivatives of the compounds of the formula I, which areto be used as starting compounds, may be prepared by customary methodsas described, for example, in the said standard works and patentapplications, for example, by reacting compounds which conform to theformulae II and III, with, however, at least one of these compoundscontaining a protective group in place of a H atom.

The liberation of the compounds of the formula I from their functionalderivatives is, for example, achieved--depending on the protective groupused--with strong acids, expediently with trifluoroacetic acid orperchloric acid, but also with other strong inorganic acids, such ashydrochloric acid or sulfuric acid, strong organic carboxylic acids,such as benzenesulfonic acid or p-toluenesulfonic acid. It is possible,but not always necessary, for an inert solvent to be present inaddition.

Inert solvents which are suitable are preferably organic, for example,carboxylic acids, such as acetic acid, ethers, such as tetrahydrofuranor dioxane, amides, such as dimethylformamides (DMF), halogenatedcarbohydrates, such as dichloromethane, and, in addition, alcohols, suchas methanol, ethanol or isopropanol and also water. In addition,mixtures of the above-mentioned solvents are suitable. Trifluoroaceticacid is preferably used in excess without the addition of any furthersolvent, perchloric acid in the form of a mixture of acetic acid and 70%perchloric acid in the ratio of 9:1. The reaction temperatures for thecleavage are expediently about 0°-50°, preferably 15°-30° (roomtemperature).

The BOC group can be eliminated, e.g., preferably using 40%trifluoroacetic acid in dichloromethane or using, preferably, about 3-5NHCl in dioxane at, preferably, 15°-60°, and the FMOC group using,preferably, an approximately 5-20% solution of dimethylamine,diethylamine or piperidine in DMF at, preferably, 15°-50°. Eliminationof the DNP group is also achieved, for example, using, preferably, anapproximately 3-10% solution of 2-mercapto-ethanol in DMF/water at,preferably, 15°-30°.

Protective groups which can be removed by hydrogenolysis (e.g., BOM, CBZor benzyl) can be eliminated, for example, by treating with hydrogen inthe presence of a catalyst (e.g., a precious metal catalyst such aspalladium, expediently on a support such as carbon). Suitable solventsin this case are those indicated above, in particular, for example,alcohols, such as methanol or ethanol, or amides, such as DMF. As arule, a hydrogenolysis is carried out at temperatures of, preferably,about 0°-100° and under pressures of, preferably, about 1-200 bar,preferably at 20°-30° and at, preferably, 1-10 bar. Hydrogenolysis ofthe CBZ group is readily achieved, for example, on, preferably, 5-10%Pd-C in methanol at, preferably, 20°-30°.

Compounds of the formula I can also, preferably, be obtained by reactingan oxazolidinone of the formula II with a compound of the formula III.For this, use is expediently made of the methods, which are known perse, of esterification or of the N-alkylation of amines.

The leaving group Z of the formula II is preferably Cl, Br, I, C₁ -C₆-alkylsulfonyloxy, such as methanesulfonyloxy or ethanesulfonyloxy, orC₆ -C₁₀ -arylsulfonyloxy, such as benzenesulfonyloxy,p-toluenesulfonyloxy or 1- or 2-naphthalenesulfonyloxy.

The reaction is preferably carried out in the presence of an additionalbase, for example, an alkali metal or alkaline earth metal hydroxide orcarbonate, such as sodium, potassium or calcium hydroxide, or sodium,potassium or calcium carbonate, in an inert solvent, for example, ahalogenated hydrocarbon, such as dichloromethane, an ether, such as THFor dioxane, an amide, such as DMF or dimethylacetamide, or a nitrile,such as acetonitrile, at temperatures of, preferably, about -10°-200°,especially 0°-120°. If the leaving group Z is different from I, it isadvisable to add an iodide such as potassium iodide.

As a rule, the starting compounds of the formula II are novel. They canbe prepared, for example, by reacting a substituted aniline of theformula R¹ --NH₂, in which R¹ has the given meaning, with a compound ofthe formula R⁵ CH₂ --CHR⁶ --CH₂ OH (in which R⁵ is Z, R⁶ is OR⁷, R⁷ is aprotective group, or R⁵ and R⁶ together are also O) to yield a compoundof the formula R¹ --NH--CH₂ --CHR⁸ --CH₂ OH (in which R⁸ is OR⁷ or OH),where appropriate eliminating the protective group R⁷ to yield compoundsof the formula R¹ --NH--CH₂ --CH(OH)--CH₂ OH, reacting with a derivativeof carbonic acid, such as diethyl carbonate, to yield 3--R¹--5-hydroxymethyl-2-oxazolidinones, and converting the hydroxymethylgroup into a CH₂ Z group, for example, using SOCl₂, SOBr₂,methanesulfonyl chloride or p-toluenesulfonyl chloride. As a rule, thecompounds of the formula Y-B (III) are known or can be prepared inanalogy with known compounds.

Compounds of the formula I can also be obtained by reacting a compoundof the formula IV (or a reactive derivative thereof) with a reactivederivative of carbonic acid.

Suitable carbonic acid derivatives are, in particular, dialkylcarbonates, such as diethyl carbonate, and also alkyl chloroformates,such as ethyl chloroformate. The carbonic acid derivative, which isexpediently employed in excess, preferably also serves as solvent orsuspending agent. However, one of the given solvents can also be presentas long as it is inert in this reaction. It is furthermore advisable toadd a base, in particular an alkali metal alcoholate such as potassiumtert-butoxide. Reaction temperatures of preferably 0°-150°, especially70°-120°, are expediently employed.

As a rule, the starting compounds of the formula IV are novel. They canbe obtained, for example, by functionalizing the above-mentionedcompounds of the formula R¹ --NH--CH₂ --CH(OH)--CH₂ OH to yieldcompounds of the formula R¹ --NH--CH₂ --CH(OH)--CH₂ --Z and reactingwith compounds of the formula B-Y (III).

In order to prepare compounds of the formula I in which R¹ is aguanidinophenyl group, a corresponding aminophenyl compound can betreated with an amidinating agent. 1-Amidino-3,5-dimethylpyrazole ispreferred as the amidinating agent, especially when it is employed inthe form of its nitrate. The reaction is expediently carried out withaddition of a base, such as triethylamine or ethyldiisopropylamine, inan inert solvent or solvent mixture, e.g., water/dioxane, attemperatures of preferably 0°-120°, especially 60°-120°.

It is furthermore possible, in a compound of the formula I, to convertone or both of the radicals R¹ and/or B into (an) other radical(s) R¹and/or B.

In particular, cyano groups can be reduced to aminomethyl groups orconverted into amidino groups, carboxyl groups can be esterified, estergroups can be cleaved, benzyl groups can be removed hydrogenolytically,and aminomethyl groups can be converted into guanidinomethyl groups.

Cyano groups can expediently be reduced to aminomethyl groups bycatalytic hydrogenation, e.g., on Raney nickel at temperatures ofpreferably 0°-100°, especially 10°-30°, and under pressures of 1-200bar, preferably under standard pressure, in an inert solvent, e.g., in alower alcohol, such as methanol or ethanol, expediently in the presenceof ammonia. If the reaction is carried out, for example, at about 20°and 1 bar, benzyl ester or N-benzyl groups present in the startingmaterial are then preserved. If it is desired to cleave these groupshydrogenolytically, it is then expedient to use a precious metalcatalyst, preferably Pd-carbon, it being possible to add an acid such asacetic acid and also water to the solution.

In order to prepare an amidine of formula I (R¹ =amidinophenyl), ammoniacan be added to a nitrile of the formula I (R¹ =cyanophenyl). Theaddition is preferably effected in several steps by, in a known manner,(a) converting the nitrile with H₂ S into a thioamide which is convertedwith an alkylating agent, e.g., CH₃ l, into the correspondingS-alkylimidothio ester which, for its part, reacts with NH₃ to yield theamidine, (b) converting the nitrile with an alcohol, e.g., ethanol, inthe presence of HCl into the corresponding imido ester and treating thelatter with ammonia, or (c) reacting the nitrile with lithiumbis(trimethylsilyl)amide and subsequently hydrolyzing the product.

The corresponding N-hydroxyamidines of the formula I (R¹ =phenylsubstituted by HO--NH--C(--NH)--) can be obtained in an analogous mannerfrom the nitriles if procedures (a) or (b) are followed but usinghydroxylamine instead of ammonia.

For the esterification, an acid of the formula I (R² =H) can be treatedwith an excess of an alcohol of the formula R² --OH (R² =A or benzyl),expediently in the presence of a strong acid, such as hydrochloric acidor sulfuric acid, at temperature of preferably 0°-100°, especially20°-50°.

Conversely, an ester of the formula I (R² =A or benzyl) can be convertedinto the corresponding acid of the formula I (R² =H), expediently bysolvolysis in accordance with one of the above-mentioned methods, e.g.,using NaOH or KOH in water/dioxane at temperatures of preferably 0°-40°,especially 10-30°.

A base of the formula I can be converted with an acid into theassociated acid addition salt. Acids which are especially suitable forthis reaction are those which yield physiologically harmless salts.Thus, inorganic acids may be used, for example, sulfuric acid, nitricacid, hydrohalic acids, such as hydrochloric acid or hydrobromic acid,phosphoric acids, such as orthophosphoric acid, or sulfamic acid, and,in addition, organic acids, in particular aliphatic, alicyclic,araliphatic, aromatic or heterocyclic monobasic or polybasic carboxylic,sulfonic or sulfuric acids, e.g., formic acid, acetic acid,trifluoroacetic acid, propionic acid, pivalic acid, diethylacetic acid,malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid,lactic acid, tartaric acid, malic acid, citric acid, gluconic acid,ascorbic acid, nicotinic acid, isonicotinic acid, methanesulfonic acid,ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethanesulfonicacid, benzenesulfonic acid, p-toluenesulfonic acid,naphthalenemonosulfonic acid, naphthalenedisulfonic acid andlaurylsulfuric acid. Salts with physiologically unacceptable acids,e.g., picrates, may be used for isolating and/or purifying the compoundsof the formula I.

If desired, the free bases of the formula I can be liberated from theirsalts by treatment with strong bases such as sodium or potassiumhydroxide, or sodium or potassium carbonate.

It is also possible to convert carboxylic acids of the formula I (R² =H)into their metal or ammonium salts, e.g., their sodium, potassium orcalcium salts, by reaction with corresponding bases.

The compounds of the formula I contain one or more chiral centers andcan therefore be present in racemic or in optically active form.Racemates which have been obtained can be resolved mechanically orchemically into the enantiomers using methods which are known per se.Diastereomers are preferably formed from the racemic mixture by reactionwith an optically active resolving agent. Suitable resolving agents are,for example, optically active acids, such as the D and L forms oftartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelicacid, malic acid or lactic acid, or the various optically activecamphorsulfonic acids, such as β-camphorsulfonic acid.

It is also advantageous to resolve the enantiomers using a column whichis packed with an optically active resolving agent (e.g.,dinitrobenzoylphenylglycine); a mixture ofhexane/isopropanol/acetonitrile (8:2:1) is an example of a suitableeluent.

It is also possible, naturally, to obtain optically active compounds ofthe formula in accordance with the above-described methods by usingstarting compounds (e.g., those of the formula II) which are alreadyoptically active.

The novel compounds of the formula I and their physiologically harmlesssalts can be used for producing pharmaceutical preparations by bringingthem into a suitable dosage form together with at least one excipient orauxiliary substance and, if desired, together with one or moreadditional active compound(s). The preparations thus obtained can beemployed as medicaments in human or veterinary medicine. Suitableexcipient substances are organic or inorganic substances which aresuitable for enteral (e.g., oral or rectal) or parenteral administrationor for administration in the form of an inhalation spray and which donot react with the novel compounds, for example, water, vegetable oils,benzyl alcohols, polyethylene glycols, glycerol triacetate and otherfatty acid glycerides, gelatin, soya lecithin, carbohydrates, such aslactose or starch, magnesium stearate, talc and cellulose. Tablets,coated tablets, capsules, syrups, juices or drops are used, inparticular, for oral administration; film tablets and capsules havingenteric coatings or capsule shells are especially of interest.Suppositories are used for rectal administration, and solutions,preferably oily or aqueous solutions, and, in addition, suspensions,emulsions or implants are used for parenteral administration.

For administration as an inhalation spray, sprays can be used whichcontain the active compound either dissolved or suspended in apropellent gas mixture. The active compound is expediently used in thiscontext in micronized form, it being possible for one or more additionalphysiologically tolerated solvents, e.g., ethanol, to be present.Inhalation solutions can be administered with the aid of customaryinhalers. The novel compounds can also be lyophilized and the resultinglyophilizates used, for example, for producing injection preparations.The preparations indicated can be sterilized and/or can containauxiliary substances, such as preservatives, stabilizers and/or wettingagents, emulsifiers, salts for influencing the osmotic pressure,buffering substances, colorants and/or flavorings, If desired, they canalso contain one or more additional active compounds, e.g., one or morevitamins.

As a rule, the substances according to the invention are administered inanalogy with other known, commercially available, drugs, in particular,however, in analogy with the compounds described in EP-A-459256whichcorresponds to U.S. Pat. No. 5,232,931, preferably in dosages of about 5mg-1 g, in particular 50-500 mg, per dosage unit. The daily dosage ispreferably about 0.1-20 g/kg, in particular 1-10 mg/kg, of body weight.However, the special dose for each particular patient depends on a widevariety of factors, for example, on the activity of the special compoundemployed, on the age, body weight, general state of health and sex, onthe food, on the time and route of administration, on speed ofexcretion, on the combination of drugs being employed, and on theseverity of the particular disease to which the therapy applies. Oraladministration is preferred.

Suitable preparations for using the compounds as antimicrobial agentsare, for example, injection vials, ampoules, solutions, and capsules.Carriers, excipients, and further additives are mentioned in ExamplesA-E. The amount of the inventive compound in the antimicrobial agents ispreferably about 0.05-500 mg per dosage unit.

Hereinbefore and hereinafter, all temperatures are indicated in °C. Inthe following examples, "customary working-up" denotes: water is addedif necessary, the pH is adjusted to values of between 2 and 8, dependingon the constitution of the final product, the mixture is extracted withethyl acetate or dichloromethane, the phases are separated, the organicphase is dried over sodium sulfate and concentrated by evaporation, andthe product is purified by chromatography on silica gel and/or bycrystallization.

Without further elaboration, it is believed that one skilled in the artcan, using the preceding description, utilize the present invention toits fullest extent. The following preferred specific embodiments are,therefore, to be construed as merely illustrative, and not limitative ofthe remainder of the disclosure in any way whatsoever.

In the foregoing and in the following examples, unless otherwiseindicated, all parts and percentages are by weight.

The entire disclosure of all applications, patents and publications,cited above and below, and of corresponding German application P 43 32384.7, filed Sep. 23, 1993, are hereby incorporated by reference.

EXAMPLES Example 1

1 Equivalent of NaH is added to a solution of 1.7 g of Nap-methoxycarbonylmethylphenoxide (obtainable by convertingp-hydroxybenzyl cyanide into the corresponding carboxylic acid,esterifying with methanol to give p-methoxycarbonylmethylphenol andsubsequently converting the latter into the phenoxide) in 20 ml ofdimethylformamide (DMF), and the mixture is stirred at room temperaturefor 30 min. After that, 3.0 g of3-p-cyanophenyl-5-methanesulfonyloxymethyloxazolidin-2-one ("A")(obtainable by reacting p-aminobenzonitrile with 2,3-epoxypropan-1-ol togive p-(N-2,3-dihydroxypropylamino)benzonitrile, reacting the latterwith diethyl carbonate in the presence of K tert-butoxide to give3-p-cyanophenyl-5-hydroxymethyloxazolidin-2-one and subsequentlyesterifying the latter with methanesulfone chloride), dissolved in 10 mlof DMF, are added and the mixture is once again stirred at roomtemperature for 15 min. Following removal of the solvent, and thecustomary working-up,3-p-cyanophenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-oneis obtained, M.p. 114°-115°.

The following compounds are obtained in an analogous manner by reacting"A"

with Na o-methoxycarbonylmethylphenoxide:

3-p-cyanophenyl-5-(o-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one,M⁺ +1=366;

with Na m-methoxycarbonylmethylphenoxide:

3-p-cyanophenyl-5-(m-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one,M.p. 129°-130°;

with Na 2,4-bis(methoxycarbonylmethyl)phenoxide:

3-p-cyanophenyl-5-[2,4-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with Na 2,5-bis(methoxycarbonylmethyl)phenoxide:

3-p-cyanophenyl-5-[2,5-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with Na 2,6-bis(methoxycarbonylmethyl)phenoxide:

3-p-cyanophenyl-5-[2,6-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with Na 3,4-bis(methoxycarbonylmethyl)phenoxide:

3-p-cyanophenyl-5-[3,4-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with Na 3,5-bis(methoxycarbonylmethyl)phenoxide:

3-p-cyanophenyl-5-[3,5-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with 2-methoxycarbonylmethyl-4-hydroxythiophene Na salt:

3-p-cyanophenyl-5-(2-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

with 3-methoxycarbonylmethyl-4-hydroxythiophene Na salt:

3-p-cyanophenyl-5-(3-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

with 2-methoxycarbonylmethyl-3-hydroxythiophene Na salt:

3-p-cyanophenyl-5-(2-methoxycarbonylmethylthien-3-yloxymethyl)oxazolidin-2-one;

with 2-methoxycarbonylmethyl-4-hydroxypyrrole Na salt:

3-p-cyanophenyl-5-(2-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

with 3-methoxycarbonylmethyl-4-hydroxypyrrole Na salt:

3-p-cyanophenyl-5-(3-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

with 2-methoxycarbonylmethyl-3-carboxy-4-hydroxypyrrole Na salt:

3-p-cyanophenyl-5-(2-methoxycarbonylmethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one;

with 2-carboxy-3-hydroxy-5-methoxycarbonylmethylpyrrole Na salt:

3-p-cyanophenyl-5-(2-carboxy-5-methoxycarbonylmethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 2

A solution of 0.9 g of3-p-cyanophenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one(M.p. 114°-115°) in 40 ml of a 10% methanolic solution of NH₃ ishydrogenated on 0.6 g of Raney Ni at room temperature and at 1 bar untilH₂ uptake is complete. Following filtration and concentration byevaporation, the customary working-up gives3-p-aminomethylphenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one.

The following compounds are obtained in an analogous manner byhydrogenating the corresponding nitriles:

3-p-aminomethylphenyl-5-(o-methoxycarbonylmethylphenoxymethyl)-oxazolidin-2-one;

3-p-aminomethylphenyl-5-(m-methoxycarbonylmethylphenoxymethyl)-oxazolidin-2-one;

3-p-aminomethylphenyl-5-[2,4-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-[2,5-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-[2,6-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-[3,4-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-[3,5-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(3-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-methoxycarbonylmethylthien-3-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(3-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-methoxycarbonylmethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-carboxy-5-methoxycarbonylmethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 3

2.4 g of3-p-aminomethylphenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-oneare dissolved in 20 ml of dichloromethane, 12 ml of trifluoroacetic acidare added, and the mixture is stirred at room temperature for 20 min.After concentrating by evaporation, and after the customary working-up,3-p-aminomethylphenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-oneis obtained.

The following carboxylic acids are obtained in an analogous manner byhydrolyzing the corresponding esters:

3-p-cyanophenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-(o-carboxymethylphenoxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-(m-carboxymethylphenoxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-[2,4-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-cyanophenyl-5-[2,5-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-cyanophenyl-5-[2,6-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-cyanophenylo5-[3,4-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-cyanophenyl-5-[3,5-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-cyanophenyl-5-(2-carboxymethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-(3-carboxymethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-(2-carboxymethylthien-3-yloxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-(2-carboxymethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-(3-carboxymethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-(2-carboxymethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-cyanophenyl-5-(2-carboxy-5-carboxymethylpyrrol-3-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(o-carboxymethylphenoxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(m-carboxymethylphenoxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-[2,4-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-[2,5-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-[2,6-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-[3,4-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-[3,5-bis(carboxymethyl)phenoxymethyl]oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-carboxymethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(3-carboxymethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-carboxymethylthien-3-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-carboxymethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(3-carboxymethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-carboxymethyl-3-carboxypyrroI-4-yloxymethyl)oxazolidin-2-one;

3-p-aminomethylphenyl-5-(2-carboxy-5-carboxymethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 4

20 ml of a 20% solution of NaOH are added to a solution of 0.6 g of3-p-aminomethylphenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-onein 20 ml of THF, and the mixture is stirred at room temperature for 24h.3-p-Aminomethylphenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-oneNa salt is obtained, M.p. 286°-287°.

Example 5

0.17 ml of ethyldiisopropylamine is added to a solution of 0.2 g of1-amidino-3,5-dimethylpyrazole nitrate in 17 ml of dioxane and 5 ml ofwater, and the mixture is stirred for 15 min. 0.4 g of3-p-aminomethylphenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-oneis subsequently added and the mixture is boiled for 30 h, concentratedby evaporation, and worked up in the customary manner.3-p-Guanidinomethylphenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-oneis obtained.

The following are obtained in an analogous manner

with3-p-aminomethylphenyl-5-(o-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-(o-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one;

with3-p-aminomethylphenyl-5-(m-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-(m-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one;

with3-p-aminomethylphenyl-5-[2,4-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-[2,4-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with3-p-aminomethylphenyl-5-[2,5-bis(methoxycarbonylmethyl)phenoxymethoyl]oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-[2,5-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with3-p-aminomethylphenyl-5-[2,6-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-[2,6-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with3-p-aminomethylphenyl-5-[3,4-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-[3,4-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with3-p-aminomethylphenyl-5-[3,5-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-[3,5-bis(methoxycarbonylmethyl)phenoxymethyl]oxazolidin-2-one;

with3-p-aminomethylphenyl-5-(2-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-(2-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

with3-p-aminomethylphenyl-5-(3-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-(3-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

with3-p-aminomethylphenyl-5-(2-methoxycarbonylmethylthien-3-yloxymethyl)oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-(2-methoxycarbonylmethylthien-3-yloxymethyl)oxazolidin-2-one;

with3-p-aminomethylphenyl-5-(2-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-(2-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

with3-p-aminomethylphenyl-5-(3-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-(3-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

with3-p-aminomethylphenyl-5-(2-methoxycarbonylmethyl-3-carboxypyrrol-yloxymethyl)oxazolidin-2-one:

3-p-guanidinoreethylphenyl-5-(2-methoxycarbonylmethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one;

with3-p-aminomethylphenyl-5-(2-carboxy-5-methoxycarbonylmethylpyrrol-3-yloxymethyl)oxazolidin-2-one:

3-p-guanidinomethylphenyl-5-(2-carboxy-5-methoxycarbonylmethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 6

H₂ S gas is passed, at -10°, into a solution of 1.2 g of3-p-cyanophenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one(obtainable in accordance with Example 1) in 50 ml of pyridine and 7 mlof triethylamine. The mixture is subsequently stirred at roomtemperature for 14 h and concentrated by evaporation; the residue isdissolved in 50 ml of acetone and treated with 9 ml of methyl iodide.After this mixture has been stirred for a further 6 h, it is filteredand the residue is washed with 5 ml of acetone and dissolved in 30 ml ofmethanol; 4.6 g of ammonium acetate are added to this solution, which isstirred at room temperature for 24 h. Following the customaryworking-up,3-p-amidinophenyl-5-(p-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one(semihydriodide) is obtained, M.p. 151°-152°.

The following are obtained in an analogous manner

from3-p-cyanophenyl-5-(o-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(o-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one(hydriodide), M⁺ +1 =384;

from3-p-cyanophenyl-5-(m-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(m-methoxycarbonylmethylphenoxymethyl)oxazolidin-2-one(hydriodide), M⁺ 1=384;

from3-p-cyanophenyl-5-[2,4-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one:

3-p-amidinophenyl-5-[2,4-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one;

from3-p-cyanophenyl-5-[2,5-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one:

3-p-amidinophenyl-5-[2,5-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one;

from3-p-cyanophenyl-5-[2,6-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one:

3-p-amidinophenyl-5-[2,6-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one;

from3-p-cyanophenyl-5-[3,4-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one:

3-p-amidinophenyl-5-[3,4-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one;

from3-p-cyanophenyl-5-[3,5-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one:

3-p-amidinophenyl-5-[3,5-bis(methoxycarbonylmethyl)phenoxymethyl]-oxazolidin-2-one;

from3-p-cyanophenyl-5-(2-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(2-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

from3-p-cyanophenyl-5-(3-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(3-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

from3-p-cyanophenyl-5-(2-methoxycarbonylmethylthien-3-yloxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(2-methoxycarbonylmethylthien-3-yloxymethyl)oxazolidin-2-one;

from3-p-cyanophenyl-5-(2-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(2-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

from3-p-cyanophenyl-5-(3-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(3-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

from3-p-cyanophenyl-5-(2-methoxycarbonylmethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(2-methoxycarbonylmethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one;

from3-p-cyanophenyl-5-(2-carboxy-5-methoxycarbonylmethylpyrrol-3-yl-oxymethyl)oxazolidin-2-one:

3-p-amidinophenyl-5-(2-carboxy-5-methoxycarbonylmethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 7

The following carboxylic acids are obtained, in analogy with Example 3,by hydrolyzing the corresponding esters from Example 6:

3-p-amidinophenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-one, M.p.281°;

3-p-amidinophenyl-5-(o-carboxymethylphenoxymethyl)oxazolidin-2-one, M.p.274°;

3-p-amidinophenyl-5-(m-carboxymethylphenoxymethyl)oxazolidin-2-one(hydrochloride), M.p. 271°;

3-p-amidinophenyl-5-[2,4-bis(carboxymethyl)phenoxymethyl]oxazolidin-one;

3-p-amidinophenyl-5-[2,5-bis(carboxymethyl)phenoxymethyl]oxazolidin-one;

3-p-amidinophenyl-5-[2,6-bis(carboxymethyl)phenoxymethyl]oxazolidin-one;

3-p-amidinophenyl-5-[3,4-bis(carboxymethyl)phenoxymethyl]oxazolidin-one;

3-p-amidinophenyl-5-[3,5-bis(carboxymethyl)phenoxymethyl]oxazolidin-one;

3-p-amidinophenyl-5-(2-carboxymethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(3-carboxymethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxymethylthien-3-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxymethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(3-carboxymethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxymethyl-3-carboxypyrrol-4-yloxymethyl)-oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxy-5-carboxymethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 8

The following carboxylic acids are obtained, in analogy with Example 3,by hydrolyzing the corresponding esters from Example 5:

3-p-guanidinomethylphenyl-5-(p-carboxymethylphenoxymethyl)oxazolidin-2-one,M.p.>300°;

3-p-guanidinomethylphenyl-5-(o-carboxymethylphenoxymethyl)oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-(m-carboxymethylphenoxymethyl)oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-[2,4-bis(carboxymethyl)phenoxymethyl]-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-[2,5-bis(carboxymethyl)phenoxymethyl]-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-[2,6-bis(carboxymethyl)phenoxymethyl]-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-[3,4-bis(carboxymethyl)phenoxymethyl]-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-[3,5-bis(carboxymethyl)phenoxymethyl]-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-(2-carboxymethylthien-4-yloxymethyl)-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-(3-carboxymethylthien-4-yloxymethyl)-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-(2-carboxymethylthiophen-3-yloxymethyl)-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-(2-carboxymethylpyrrol-4-yloxymethyl)-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-(3-carboxymethylpyrrol-4-yloxymethyl)-oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-(2-carboxymethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-guanidinomethylphenyl-5-(2-carboxy-5-carboxymethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 9

3-p-Cyanophenyl-5-(p-methoxycarbonylmethylphenylthiomethyl)oxazolidin-2-oneis obtained, in analogy with Example 1, proceeding from Nap-methoxycarbonylmethylthiophenoxide (obtainable by convertingp-mercaptobenzyl cyanide into the corresponding carboxylic acid,esterifying with methanol to give p-methoxycarbonylmethylthiophenol andsubsequently converting the latter into the thiophenoxide), by reactionwith 3-p-cyanophenyl-5-methane-sulfonyloxymethyloxazolidin-2-one ("A")(obtainable in accordance with Example 1).

The following can be obtained in an analogous manner by reaction of "A"

with Na o-methoxycarbonylmethylthiophenoxide:

3-p-cyanophenyl-5-(o-methoxycarbonylmethylphenylthiomethyl)oxazolidin-2-one;

with Na m-methoxycarbonylmethylthiophenoxide:

3-p-cyanophenyl-5-(m-methoxycarbonylmethylphenylthiomethyl)oxazolidin-2-one;

with Na 2,4-bis(methoxycarbonylmethyl)thiophenoxide:

3-p-cyanophenyl-5-[2,4-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxazolidin-2-one;

with Na 2,5-bis(methoxycarbonylmethyl)thiophenoxide:

3-p-cyanophenyl-5-[2,5-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxazolidin-2-one;

with Na 2,6-bis(methoxycarbonylmethyl)thiophenoxide:

3-p-cyanophenyl-5-[2,6-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxazolidin-2-one;

with Na 3,4-bis(methoxycarbonylmethyl)thiophenoxide:

3-p-cyanophenyl-5-[3,4-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxazolidin-2-one;

with Na 3,5-bis(methoxycarbonylmethyl)thiophenoxide:

3-p-cyanophenyl-5-[3,5-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxazolidin-2-one;

with 2-methoxycarbonylmethyl-4-hydroxythiophene Na salt:

3-p-cyanophenyl-5-(2-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

with 3-methoxycarbonylmethyl-4-hydroxythiophene Na salt:

3-p-cyanophenyl-5-(3-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

with 2-methoxycarbonylmethyl-3-hydroxythiophene Na salt:

3-p-cyanophenyl-5-(2-methoxycarbonylmethylthien-3-yloxymethyl)oxazolidin-2-one;

with 2-methoxycarbonylmethyl-4-hydroxypyrrole Na salt:

3-p-cyanophenyl-5-(2-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

with 3-methoxycarbonylmethyl-4-hydroxypyrrole Na salt:

3-p-cyanophenyl-5-(3-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

with 2-methoxycarbonylmethyl-3-carboxy-4-hydroxypyrrole Na salt:

3-p-cyanophenyl-5-(2-methoxycarbonylmethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one;

with 2-carboxy-3-hydroxy-5-methoxycarbonylmethylpyrrole Na salt:

3-p-cyanophenyl-5-(2-carboxy-5-methoxycarbonylmethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 10

The following amidinophenyloxazolidin-2-one derivatives are obtained inanalogy with Example 6, proceeding from the nitriles from Example 9:

3-p-amidinophenyl-5-(p-methoxycarbonylmethylphenylthiomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(o-methoxycarbonylmethylphenylthiomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(m-methoxycarbonylmethylphenylthiomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-[2,4-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxszolidin-2-one;

3-p-amidinophenyl-5-[2,5-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxazolidin-2-one;

3-p-amidinophenyl-5-[2,6-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxazolidin-2-one;

3-p-amidinophenyl-5-[3,4-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxszolidin-2-one;

3-p-amidinophenyl-5-[3,5-bis(methoxycarbonylmethyl)phenylthiomethyl]-oxazolidin-2-one;

3-p-amidinophenyl-5-(2-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-smidinophenyl-5-(3-methoxycarbonylmethylthien-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-methoxycarbonylmethylthien-3-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(3-methoxycarbonylmethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-methoxycarbonylmethyl-3-carboxypyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxy-5-methoxycarbonylmethylpyrrol-3-yloxymethyl)oxazolidin-2-one.

Example 11

The following carboxylic acids are obtained in analogy with Example 3 byhydrolyzing the corresponding esters from Example 10:

3-p-amidinophenyl-5-(p-carboxymethylphenylthiomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(o-carboxymethylphenylthiomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(m-carboxymethylphenylthiomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-[2,4-bis(carboxymethyl)phenylthiomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-[2,5-bis(carboxymethyl)phenylthiomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-[2,6-bis(carboxymethyl)phenylthiomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-[3,4-bis(carboxymethyl)phenylthiomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-[3,5-bis(carboxymethyl)phenylthiomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxymethylthiophen-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(3-carboxymethylthiophen-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxymethylthiophen-3-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxymethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(3-carboxymethylpyrrol-4-yloxymethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxymethyl-3-carboxypyrrol-4-yloxymethyl)-oxazolidin-2-one;

3-p-amidinophenyl-5-(2-carboxy-5-carboxymethylpyrrol-3-yloxymethyl)-oxazolidin-2-one.

Example 12

3-p-Cyanophenyl-5-(p-methoxycarbonylmethylphenylaminomethyl)oxazolidin-2-oneis obtained in analogy with Example 1, proceeding frompomethoxycarbonylmethylaniline (obtainable by converting p-aminobenzylcyanide into p-aminophenylacetic acid and esterifying the latter withmethanol), by reaction with3-p-cyanophenyl-5-methanesulfonyloxymethyloxazolidin-2-one ("A")(obtainable in accordance with Example 1).

The following are obtained in an analogous manner by reaction of "A"

with o-methoxycarbonylmethylaniline:

3-p-cyanophenyl-5-(o-methoxycarbonylmethylphenylaminomethyl)oxazolidin-2-one;

with m-methoxycarbonylmethylaniline:

3-p-cyanophenyl-5-(m-methoxycarbonylmethylphenylaminomethyl)oxazolidin-2-one;

with 2,4-bis(methoxycarbonylmethyl)aniline:

3-p-cyanophenyl-5-[2,4-bis(methoxycarbonylmethyl)phenylaminomethyl]oxazolidin-2-one;

with 2,5-bis(methoxycarbonylmethyl)aniline:

3-p-cyanophenyl-5-[2,5-bis(methoxycarbonylmethyl)phenylaminomethyl]oxazolidin-2-one;

with 3,4-bis(methoxycarbonylmethyl)aniline:

3-p-cyanophenyl-5-[3,4-bis(methoxycarbonylmethyl)phenylaminomethyl]oxazolidin-2-one.

Example 13

The following amidinophenyloxazolidin-2-one derivatives are obtained inanalogy with Example 6, proceeding from the nitriles from Example 9:

3-p-amidinophenyl-5-(p-methoxycarbonylmethylphenylaminomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(o-methoxycarbonylmethylphenylaminomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(m-methoxycarbonylmethylphenylaminomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-[2,4-bis(methoxycarbonylmethyl)phenylaminomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-[2,5-bis(methoxycarbonylmethyl)phenylaminomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-[3,4-bis(methoxycarbonylmethyl)phenylaminomethyl]oxazolidin-2-one.

Example 14

The following carboxylic acids are obtained in analogy with Example 3 byhydrolyzing the corresponding esters from Example 13:

3-p-amidinophenyl-5-(p-carboxymethylphenylaminomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(o-carboxymethylphenylaminomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-(m-carboxymethylphenylaminomethyl)oxazolidin-2-one;

3-p-amidinophenyl-5-[2,4-bis(carboxymethyl)phenylaminomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-[2,5-bis(carboxymethyl)phenylaminomethyl]oxazolidin-2-one;

3-p-amidinophenyl-5-[3,4-bis(carboxymethyl)phenylaminomethyl]oxazolidin-2-one.

Example 15

3-p-Cyanophenyl-5-(p-methoxycarbonylmethylphenyI-N-methylaminomethyl)oxazolidin-2-oneis obtained in analogy with Example 1, proceeding fromp-methoxycarbonylmethyl-N-methylaniline (obtainable by convertingp-N-methylaminobenzyl cyanide into p-methylaminophenylacetic acid andesterifying the latter with methanol), by reaction with3-p-cyanophenyl-5-methanesulfonyloxymethyloxazolidin-2-one ("A")(obtainable in accordance with Example 1).

Example 16

3-p-Amidinophenyl-5-(p-methoxycarbonylmethylphenyI-N-methylamino-methyl)oxazolidin-2-oneis obtained in analogy with Example 6, proceeding from nitrile fromExample 15.

Example 17

3-p-Amidinophenyl-5-(p-carboxymethylphenyI-N-methylaminomethyl)oxazolidin-2-oneis obtained in analogy with Example 3 by hydrolyzing the ester fromExample 16.

The following examples relate to pharmaceutical preparations.

Example A: Injection Vials

A solution of 100 g of an active compound of the formula I and 5 g ofdisodium hydrogen phosphate in 3 l of doubly distilled water is adjustedto pH 6.5 with 2N hydrochloric acid, filtered sterile, filled intoinjection vials and lyophilized, and the vials are sealed in a sterilemanner. Each injection vial contains 5 mg of active compound.

Example B: Suppositories

A mixture of 20 mg of an active compound of the formula I is fused with100 g of soya lecithin and 1400 g of cocoa butter, and the mixture ispoured into molds and allowed to cool. Each suppository contains 20 mgof active compound.

Example C: Solution

A solution of 1 g of an active compound of the formula I, 9.38 g of NaH₂PO₄.2H₂ O, 28.48 g of Na₂ HPO₄.12H₂ O and 0.1 g of benzalkonium chlorideis prepared in 940 ml of doubly distilled water. The solution isadjusted to pH 6.8, made up to 1 l and sterilized by irradiation. Thissolution can be used in the form of eye drops.

Example D: Ointment

500 mg of an active compound of the formula I are mixed with 99.5 g ofpetroleum jelly under aseptic conditions.

Example E: Tablets

A mixture of 1 kg of active compound of the formula I, 4 kg of lactose,1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearateis pressed to give tablets in a customary manner, such that each tabletcontains 10 mg of active compound.

Example F: Coated Tablets

Tablets are pressed analogously to Example E and then coated in acustomary manner with a coating of sucrose, potato starch, talc,tragacanth and colorant.

Example G: Capsules

Hard gelatin capsules are filled with 2 kg of active compound of theformula I in the customary manner, such that each capsule contains 20 mgof active compound.

Example H: Ampoules

A solution of 1 kg of active compound of the formula I in 60 l of doublydistilled water is filled into ampoules and lyophilized under sterileconditions, and the ampoules are sealed in a sterile manner. Eachampoule contains 10 mg of active compound.

The preceding examples can be repeated with similar success bysubstituting the generically or specifically described reactants and/oroperating conditions of this invention for those used in the precedingexamples.

From the foregoing description, one skilled in the art can easilyascertain the essential characteristics of this invention, and withoutdeparting from the spirit and scope thereof, can make various changesand modifications of the invention to adapt it to various usages andconditions.

What is claimed is:
 1. An oxazolidinone derivative of formula I ##STR8## wherein R¹ is a phenyl radical which is unsubstituted or is monosubstituted byX is --NH-- or --NA--; B is ##STR9## or ##STR10## A is C₁₋₆ -alkyl; R² is H, A, Li, Na, K, NH₄ or benzyl; R³ is H or --(CH₂)_(n) --COOR² ; E is, in each case --CH--; Q is --NH--; m is 1, 2 or 3; and n is 0, 1, 2 or 3;or a physiologically compatible salt thereof.
 2. A compound of claim 1, which is a D form enantiomer.
 3. A compound of claim 1, which is an L form enantiomer.
 4. A compound of claim 1, wherein A is C₁₋₄ -alkyl.
 5. A compound of claim 1, wherein X is --NH-- or --NCH₃.
 6. A compound of claim 1, wherein B is:2-carboxymethylphenyl, 3-carboxymethylphenyl, 4-carboxymethylphenyl, 2-methoxycarbonylphenyl, 3-methoxycarbonylphenyl, 4-methoxycarbonylphenyl, 2-ethoxycarbonylphenyl, 3-ethoxycarbonylphenyl, 4-ethoxycarbonylphenyl, 2-carboxymethylthien-4-yl, 2-carboxymethylpyrrol-4-yl, 3-carboxymethylpyrrol-4-yl, 2,5-dicarboxymethylpyrrol-4-yl, 2,3-dicarboxymethylpyrrol-4-yl, 2-carboxymethyl-3-carboxypyrrol-4-yl, 2-carboxymethyl-5-carboxypyrrol-4-yl, 2,3-dicarboxymethylphenyl, 2,4-dicarboxymethylphenyl, 2,5-dicarboxymethylphenyl, 2,6-dicarboxymethylphenyl, 3,4-dicarboxymethylphenyl, 3,5-dicarboxymethylphenyl, or a methyl or ethyl ester thereof, or a Li, Na, K or ammonium salt thereof.
 7. A compound of claim 1, wherein R² is H, A or Na.
 8. A compound of claim 1, wherein R³ is H or carboxymethyl.
 9. A compound of claim 1, wherein Q is --S-- or --NH--.
 10. A compound of claim 1, wherein m and n are each
 1. 11. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable excipient.
 12. A composition of claim 11, wherein said composition comprises 5 mg-1 g of said compound.
 13. A compound of claim 1, which inhibits the binding of fibrinogen to fibrinogen receptor. 